Translational Development Acquisition Corp.

Translational Development Acquisition Corp., trading under the warrant ticker TDACW, is a blank-check company focused on the life sciences and biotechnology sector. The vehicle filed its annual 10-K report with the SEC on March 30, 2026, under accession number 0001104659-26-036811, indicating the company remains in its search phase for a qualifying business combination target. The SPAC's name signals an explicit orientation toward translational medicine and development-stage therapeutic companies, reflecting a specialized mandate within the broader healthcare and biopharma deal landscape. Investors and analysts tracking its status, sponsor details, and deal pipeline can access the full filing record and real-time updates by signing up for a SpacDesk account at spacdesk.com.